Does Continuous Renal Replacement Therapy with oXiris in Septic Shock Have Any Positive Impact? Single-Centre Experience with oXiris Therapy in Septic Shock Patients
Open Access
- 11 December 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7527
Abstract
Background: Renal replacement therapy with an oXiris hemofilter may be helpful for patients with acute kidney injury in conjunction with sepsis and septic shock. The aim of this study was to assess the impact of an oXiris membrane on septic shock patients. Methods: All renal replacement therapies with oXiris (Baxter, Deerfield, IL, USA) performed between January 2018 and August 2021 were retrospectively analyzed. CRRT was initiated in continuous venovenous hemodiafiltration (CVVHDF) mode using Prismaflex System (Baxter). Demographic data, starting point of infection, source control, etiology, and course of treatment were analyzed. Results: A total of 32 patients were included in the study. Most patients treated with oXiris had acute kidney injury (AKI) and required CRRT. One patient had KDIGO 1 AKI (3.1%), three patients (9.4%) had KDIGO 2 AKI, and 28 patients (87.5%) had KDIGO 3 AKI. A statistically significant decrease in vasopressin dosage was required to achieve adequate MAP after 24 and 72 h, and a statistically significant decrease in norepinephrine dosage after 72 h was observed, with no SOFA score change on days 2 and 3. Procalcitonin and lactate levels did not change after 24 and 72 h. No beneficial effect on mortality was observed. Conclusions: Treatment with an oXiris membrane can positively impact vasopressors’ requirement but not influence SOFA score, procalcitonin or lactate levels, or mortality in septic shock patients.Keywords
This publication has 27 references indexed in Scilit:
- Outcomes of extracorporeal blood purification with oXiris® membrane in critically ill patients: A systematic review and meta-analysisJournal of Critical Care, 2024
- Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease StudyThe Lancet, 2020
- Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level*Critical Care Medicine, 2018
- Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin LevelJAMA, 2018
- Sepsis and septic shockThe Lancet, 2018
- Advances in the understanding and treatment of sepsis-induced immunosuppressionNature Reviews Nephrology, 2017
- Acute kidney injury in sepsisIntensive Care Medicine, 2017
- We Underdose Antibiotics in Patients on CRRTSeminars in Dialysis, 2016
- Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012JAMA, 2014
- Early Use of Polymyxin B Hemoperfusion in Abdominal Septic ShockJAMA, 2009